Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combination Cancer Immunotherapy in Hepatocellular Carcinoma.

Literature DB >> 29662830

Combination Cancer Immunotherapy in Hepatocellular Carcinoma.

Masatoshi Kudo¹.

Abstract

Entities: Disease

Year: 2018 PMID： 29662830 PMCID： PMC5892358 DOI： 10.1159/000486487

Source DB: PubMed Journal: Liver Cancer ISSN： 1664-5553 Impact factor: 11.740

× No keyword cloud information.

20 in total

Review 1. The future of immune checkpoint therapy.

Authors: Padmanee Sharma; James P Allison
Journal: Science Date: 2015-04-03 Impact factor: 47.728

Review 2. Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.

Authors: Masatoshi Kudo
Journal: Oncology Date: 2017-02-02 Impact factor: 2.935

3. Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives.

Authors: M Kudo
Journal: Liver Cancer Date: 2016-12-15 Impact factor: 11.740

4. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors: Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal: N Engl J Med Date: 2015-04-20 Impact factor: 91.245

Review 5. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors: Padmanee Sharma; James P Allison
Journal: Cell Date: 2015-04-09 Impact factor: 41.582

6. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors: Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal: Lancet Date: 2017-04-20 Impact factor: 79.321

7. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors: Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal: N Engl J Med Date: 2014-12-06 Impact factor: 91.245

Review 8. Immune tolerance: what is unique about the liver.

Authors: Gisa Tiegs; Ansgar W Lohse
Journal: J Autoimmun Date: 2009-08-29 Impact factor: 7.094

9. Nivolumab plus ipilimumab in advanced melanoma.

Authors: Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal: N Engl J Med Date: 2013-06-02 Impact factor: 91.245

10. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma.

Authors: Eishiro Mizukoshi; Tatsuya Yamashita; Kuniaki Arai; Hajime Sunagozaka; Teruyuki Ueda; Fumitaka Arihara; Takashi Kagaya; Taro Yamashita; Kazumi Fushimi; Shuichi Kaneko
Journal: Hepatology Date: 2013-04 Impact factor: 17.425

22 in total

Combination Cancer Immunotherapy in Hepatocellular Carcinoma.

Review 1. The future of immune checkpoint therapy.

Review 2. Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.

3. Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives.

4. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Review 5. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

6. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

7. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Review 8. Immune tolerance: what is unique about the liver.

9. Nivolumab plus ipilimumab in advanced melanoma.

10. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma.

1. Pembrolizumab for the Treatment of Hepatocellular Carcinoma.

2. New treatment-induced adverse effects we need to learn as modern hepatologists.

3. Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.

4. Promising anticancer therapy: combination of immune checkpoint inhibitors and molecular-targeted agents.

5. Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials.

6. A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.

Review 7. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.

Review 8. Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma.

Review 9. The immunological and metabolic landscape in primary and metastatic liver cancer.

10. Adjuvant therapy after radical surgery for hepatocellular carcinoma: still an unmet need.